Daily Biotech Movers — 2026-11-06: A Breadth Rebound Where Every Large Decline Still Came From a Document

Friday, November 6, 2026 was the mirror image of the session before it. Of the 568 companies that returned a usable close, 416 finished higher against 149 lower — a ratio of 2.8-to-1 that reverses Thursday’s 9.8-to-1 decline — on a median move of +2.91% and a mean of +2.84%, with a standard deviation of 6.67%. 175 names rose at least 5%, only 34 fell that far, and 225 cleared the anomaly filter on price or volume. Turnover confirmed the flip: 53 companies traded at least twice their 30-day average volume and 21 at least three times.

The macro did most of the work on the way up. The S&P 500 added 0.32%, the large-cap biotech proxy rose 1.73%, the small-cap biotech proxy rose 2.58%, and the health care sector proxy slipped 0.08% — a session in which broad health care stalled while small-cap biotech, the highest-beta corner of the cohort, outperformed everything. That is the exact inverse of Thursday, when the same small-cap proxy fell 6.60% and led the cohort down. When the AI-infrastructure complex stops falling, the marginal dollar goes back to the longest-duration assets first, and the median biotech is a long-duration asset.

What did not reverse was the character of the tails. The three largest declines on the board — Biodesix at -57.01%, CVRx at -40.90% and Anika Therapeutics at -24.73% — were all decided by a filed number or a regulator’s letter, on a day when the average name in the cohort rose nearly three percent. Two of the three biggest gainers were also documents: an interim clinical dataset and a quarterly beat-and-raise. Only one of Friday’s six extremes, Onconetix, was pure capital-structure mechanics.

That is the useful shape of a rebound session. Breadth tells you the discount rate moved. The tails still tell you which companies handed the market a fact.

The 6 Classes of Mover Signal

Every anomaly-flagged move is assigned to one of six classes, and the class is what separates information from mechanics. Class 1 — halt-release: a name resumes trading after a regulatory or news halt and gaps to a new equilibrium, and reverse-split or capital-reorganisation events behave the same way mechanically. Class 2 — single-stock binary catalyst: a clinical readout, regulatory decision, earnings print or programme failure resets the equity’s valuation in one session. Class 3 — buyout and strategic capital: an acquisition, tender, divestiture, licensing deal, financing, registration or split event reprices the float against a control value or against the supply of paper. Class 4 — sector rotation: the name moves with its bucket rather than with its own news. Class 5 — sell-the-news: a disclosure is sold because the outcome was already in the price. Class 6 — stealth accumulation or distribution: the price barely moves while turnover runs multiples of normal.

Friday’s board is almost entirely Class 2, with one Class 1 outlier. On the winning side, MetaVia is a Class 2 clinical readout reaching the tape with a one-session lag, Fulgent Genetics is a Class 2 earnings beat with a guidance improvement, and Onconetix is Class 1 reverse-split mechanics. On the losing side, Biodesix is a Class 2 revenue miss and guidance cut, CVRx is a Class 2 miss compounded by reimbursement erosion, and Anika is a Class 2 regulatory setback — a pre-market approval application the FDA called not approvable — layered on a flat 2027 outlook.

There is no Class 6 print on the board: with 416 names rising, the flat-price-heavy-volume signature that marks quiet institutional positioning had almost nowhere to hide, and the volume anomaly table is populated by names that also moved.

The sector map is where Class 4 lives, and Friday’s map is unusually clean. Psychedelics printed +7.51% across just four names — the top line on the board and a sample too small to read as a rotation — and among buckets with a real sample genetics and genomics led at +7.07% across seven names (median +3.72%), with AI and machine learning up 6.85% across five, antibodies 4.82% across 42 and small molecule pharma 4.35% across 150 names on a +3.60% median — the largest bucket in the cohort, and it moved almost exactly with the cohort median. The laggards were the cash-generating device buckets: devices — implants at -4.40% across ten names on a 0.00% median, devices — surgical at -1.50% across 29 on a -2.57% median, and diagnostics at -0.20% across 30 on a +1.54% median.

Read those three carefully, because the average and the median disagree, and the gap is the story. A bucket with a deeply negative average and a flat median is one name, not a rotation: devices — implants printed a 0.00% median while its average fell 4.40%, and the entire distance is a single stock that lost two-fifths of its value. Same for diagnostics, where the average is slightly negative and the median is positive by 1.54 points. Only devices — surgical has both statistics pointing the same way, and even there a 12.79% decline on elevated volume did a large share of the work. On a day when the median company rose 2.9%, a bucket average is a fragile statistic.

Top 3 Winners — What Drove Them

MTVA — MetaVia, +31.19% to $1.43 on 9.06x volume

MetaVia closed at $1.43, up 31.19%, on 968,303 shares against a 30-day average near 107,000 — a 9.06x volume ratio — after opening at the $1.09 prior close and trading as high as $1.44, leaving the stock 89% below its 52-week high of $13.42 but 47% above its $0.97 low (MetaVia — DA-1726 Phase 1 Part 3B interim data, 8-K summary of the interim results, Kalkine — why MTVA surged 23.85%, TipRanks — positive interim results for DA-1726).

This is a Class 2 clinical catalyst with a one-session lag, and the lag is the interesting part. The data were released on November 5, and the stock fell 13.8% that session before the market repriced it on Friday. What the release contained, in an otherwise healthy adult obesity population of 15 treated and four placebo participants: a 68% placebo-adjusted reduction in liver fat and a 13.5% placebo-adjusted reduction in body weight at Day 109 of once-weekly DA-1726, an oxyntomodulin analogue hitting both the GLP-1 and glucagon receptors. In the MRI substudy, 10 of 12 treated participants achieved at least a 30% relative liver-fat reduction versus none on placebo, and all five treated participants who entered with liver steatosis reached MRI-PDFF below 5%. HbA1c fell 0.24 points versus placebo, lean mass was relatively preserved, and no gastrointestinal adverse event caused discontinuation.

The forward calendar is what the tape is now paying for. MetaVia guides full Part 3A and 3B data in the first quarter of 2027 and a 48-week, non-biopsy Phase 2 in MetALD and ALD — a population the company sizes at 10.7 million US adults with no approved therapy — targeted for the second half of 2027. Against that sits $12.6 million of cash at June 30, no debt, and Dong-A ST at 26.8% of the register. At a market value near $9 million, a 9x volume day on a five-day momentum that was -8.4% going in is a repricing off a very low base rather than the start of an accumulation trend: the same float that made Thursday’s -13.8% possible made Friday’s +31.19% possible.

FLGT — Fulgent Genetics, +27.22% to $23.74 on 3.86x volume

Fulgent closed at $23.74, up 27.22%, on 1.10 million shares against a 30-day average near 284,000 — a 3.86x volume ratio — gapping up from an $18.66 prior close and trading between $19.64 and $23.85, leaving the stock 24% below its 52-week high of $31.04 and 76% above its $13.46 low (Motley Fool — FLGT third-quarter 2026 call, GuruFocus — revenue climbs 8% as anatomic pathology surges 57%, Seeking Alpha — Q3 2026 transcript).

This is the cleanest Class 2 earnings catalyst on the board. Third-quarter revenue of $90.4 million grew 8% year over year and 6% sequentially; adjusted EPS of -$0.09 beat a -$0.65 consensus by 56 cents, and revenue cleared estimates by $4.1 million. The composition mattered more than the headline: anatomic pathology revenue rose 57% to $40.9 million on the Bako Diagnostics and StrataDx integrations, offsetting a molecular business still working through a large-customer transition and a billing-system migration that depressed collections earlier in the year.

Guidance did the rest. Full-year non-GAAP loss guidance improved to $1.65–$1.75 a share from $2.22–$2.35, the $330–340 million revenue range was reaffirmed, and year-end cash is now guided to roughly $630 million, up from a prior $610 million forecast, after 4.1 million shares repurchased year to date and with $75.6 million still authorised. The stock had closed 5.59% lower at $18.58 on the day of the print with five-day momentum at -13.9% — the market had been positioned for the opposite announcement, which is precisely why the gap held.

ONCO — Onconetix, +26.59% to $6.95 on split-adjusted volume

Onconetix closed at $6.95, up 26.59%, on 710,446 shares — a reported 0.14x volume ratio that is an artefact of the split, not an absence of interest — after trading between $5.61 and $7.82 on the first session of split-adjusted trading (Onconetix — reverse stock split announcement, Yahoo Finance — reverse split, Investing.com — 1-for-10 reverse split effective November 6).

This is Class 1 mechanics with no informational content about the business. The company’s 1-for-10 reverse split took effect at 12:01 a.m. ET on November 6, cutting outstanding shares from roughly 5,886,774 to about 588,677 and assigning a new CUSIP — the second such operation in 2026, taking the cumulative ratio to 1-for-100.

The arithmetic explains the percentage. A 0.14x volume ratio against a 30-day average of nearly 5.0 million shares is being measured in pre-split units; adjusted for the ten-to-one conversion, Friday’s turnover was close to normal. And the 26.59% gain is a $5.49 pre-split-equivalent close repricing against a float a tenth of its former size, in a name where a few hundred thousand dollars of flow sets the print. Meanwhile the operating story is unchanged: Onconetix is a commercial-stage oncology company whose principal asset is Proclarix, an IVDR-approved prostate-cancer diagnostic sold in selected European laboratories and slated for US launch as a lab-developed test through a Labcorp licence, with a market value in the low single-digit millions. Treat Friday’s gain as a share-count event, not a signal.

Top 3 Losers — What Drove Them

BDSX — Biodesix, -57.01% to $8.53 on 15.82x volume

Biodesix closed at $8.53, down 57.01%, on 1.59 million shares against a 30-day average near 100,000 — a 15.82x volume ratio, the heaviest on the board — gapping down from $19.84 and trading between $7.99 and $13.03, finishing 73% below its 52-week high of $31.97 (MarketWatch — Biodesix shares fall on lower outlook, Benzinga — stock crashes after Q3 miss and 2026 outlook cut, Motley Fool — BDSX Q3 2026 transcript, GlobeNewswire — securities investigation announced).

The quarter was mediocre; the guide was the event. Revenue of $24.0 million grew 10% but missed a $27.4 million consensus by roughly 12%, and the company cut full-year 2026 revenue guidance to $101–103 million from $108–114 million — an 8% reduction at the midpoint and the second trim of the year. Diagnostic testing revenue rose 16% to $23.0 million on test volumes up 24% to about 19,400, with gross margin steady at 81%; what broke was the revenue per test, down 6% on a mix shift toward Nodify CDT, plus development services revenue that halved to $1.0 million as customer projects slipped into 2027.

Management attributed the shortfall to execution and timing — 101 sales representatives in the field against plan, after turnover in newer primary-care territories, plus heavier-than-expected seasonality — and pointed to October as the year’s strongest month for physician additions. The market’s response was to reprice a multiple built on the old guide: the stock had roughly tripled year to date before the print, closed 7.68% lower at $19.84 on the day of the release, and gave back more than half its remaining value on Friday. A securities-law firm opened an investigation into the disclosures the same afternoon. When a growth diagnostics story misses guidance twice in a year, the question stops being about the quarter and becomes about credibility.

CVRX — CVRx, -40.90% to $0.87 on 8.81x volume

CVRx closed at $0.87, down 40.90%, on 5.39 million shares against a 30-day average near 612,000 — an 8.81x volume ratio — down from $1.47, trading between $0.77 and $1.25 and printing a new 52-week floor, now 92% below its $10.63 high (TradingKey — Q3 call, guidance cut on reimbursement delays, Motley Fool — CVRX Q3 2026 transcript, Tickeron — Q3 recap and revised outlook, MarketBeat — Q3 results and report).

This is Class 2 earnings plus a reimbursement mechanism the company does not control, and it is the second consecutive guidance cut. Revenue of $13.8 million fell 6.1% year over year — the top line contracted after growing 16% two quarters earlier — and came in just below consensus, with an adjusted loss of $0.52 a share. Full-year 2026 revenue guidance came down to $56–57 million from $58–60 million, and fourth-quarter guidance of $11.7–12.7 million implies a further sequential decline.

The cause is unusually legible for a medtech miss. The 30-day approval rate for UnitedHealthcare prior authorisations managed by CVRx fell to about 12%, against a high of 83% in 2025 — a reimbursement gate in front of Barostim, a device that depends on a specialist referral and authorisation chain. Management is protecting gross margin guidance at 86–87% and cutting baseline operating expense to a $99–101 million range, and the same release disclosed a chief financial officer transition. None of that answers the question the equity is now asking, which is whether a therapy requiring prior authorisation can grow at all when the largest payer’s approval rate falls by seven-eighths.

ANIK — Anika Therapeutics, -24.73% to $14.55 on 2.72x volume

Anika closed at $14.55, down 24.73%, on 294,124 shares against a 30-day average near 108,000 — a 2.72x volume ratio — down from $19.33 and trading as low as $13.92, leaving the stock 36% below its 52-week high of $22.88 and 61% above its $9.01 low (Anika — third-quarter 2026 results as reported, Benzinga — ANIK Q3 2026 call transcript, MarketBeat — what Anika said on its Q3 call).

This is the most instructive of the three declines, because the quarter was good. Revenue of $30.6 million grew 10%, commercial channel revenue hit a record $14.0 million (+17%) and OEM revenue rose 5%, gross margin expanded to 62% from 56%, the continuing-operations loss narrowed to $0.02 a share from $0.22, and management raised the low end of 2026 revenue growth guidance to 6–10% while lifting the adjusted EBITDA margin outlook to 15–17%. A new ten-year Hyvisc distribution agreement with Boehringer Ingelheim carries improved pricing and about $8 million of expected payments.

The stock fell on two things the income statement does not show. First, the FDA found the Hyalofast pre-market approval application not approvable, primarily because of its clinical data — removing the US leg of a cartilage-regeneration programme the market had been capitalising, and one that appears nowhere in forward guidance. Second, the 2027 frame is thin: management reaffirmed total company revenue growth of flat to 5%, with OEM revenue flat to modestly lower, and cut 2026 commercial channel growth guidance to 9–13% from 12–18% on softer US elective surgery trends. Cingal’s new drug application is now guided for submission before the end of 2027. A company growing 10% today but guiding flat to 5% next year, with its US pipeline asset rejected, is a de-rating even when the current quarter beats.

The Cross-Cutting Pattern

The rotation on Friday was not between sectors — it was back into duration. Every bucket whose valuation leans on a 2029 or 2030 cash flow outperformed: genetics and genomics +7.07%, AI and machine learning +6.85%, antibodies +4.82%, RNA, peptide and gene therapy +3.02% across 27 names. Every bucket whose valuation leans on procedures performed this quarter lagged: devices — surgical -1.50%, devices — implants -4.40%, devices — miscellaneous +0.26%, diagnostics -0.20%. That is Thursday’s trade run in reverse, and it fits the macro tape: when the S&P 500 stops falling and the small-cap biotech proxy outperforms both the S&P and broad health care, the market is rotating back to the part of the cohort with the longest optionality.

But the sector read is not where the information was. Look again at the six extremes and their buckets. Fulgent Genetics sits in genetics and genomics, the best bucket of any real size, and its +27.22% is 20 points better than that sector’s average. MetaVia sits in small molecule pharma, a 150-name bucket that rose 4.35%, and its +31.19% is 27 points better than that. CVRx sits in devices — implants, a bucket with a 0.00% median, and it accounts for essentially the whole of that bucket’s -4.40% average. Biodesix sits in diagnostics, where the median name rose 1.54% while the average fell 0.20% — and one -57.01% print is the entire difference.

The pattern underneath is about what kind of number a company can hand the market. Fulgent handed it $90.4 million of revenue, a 56-cent EPS beat and an improved loss guide. MetaVia handed it 68% placebo-adjusted liver-fat reduction at Day 109. Onconetix handed it a share-count conversion, which is a number of a different kind — internally generated, value-neutral, and legible as mechanics. Biodesix handed it a cut guide. CVRx handed it a 12% prior-authorisation approval rate. Anika handed it an FDA letter and a flat 2027.

Two of the three winners were repriced because a document contained a fact that changed expected cash flows. The third was repriced because its share count changed by a factor of ten. All three losers lost value for the same reason the winners gained: something was written down, and the market could read it.

The 5 Data Points That Matter

1. Relative performance against the cohort median is the only clean comparison on a breadth day. The median name rose 2.91%, the small-cap biotech proxy 2.58% and the large-cap proxy 1.73%. MTVA beat the median by 28.3 points, FLGT by 24.3 and ONCO by 23.7, while BDSX trailed it by 59.9 points, CVRX by 43.8 and ANIK by 27.6. On a session where 416 of 568 names rose, a five percent move is close to the base rate — 175 names cleared it — so distance from the median, not the raw percentage, is what identifies a company-specific event.

2. Volume ratio separates conviction from mechanics, but notional value separates size from noise. BDSX traded 15.82x normal volume on 1.59 million shares at $8.53, roughly $13.6 million of notional. CVRX traded 8.81x on 5.39 million shares at $0.87, about $4.7 million. MTVA traded 9.06x on 968,303 shares at $1.43, about $1.4 million, and ANIK 2.72x on 294,124 shares at $14.55, about $4.3 million. FLGT’s 3.86x on 1.10 million shares at $23.74 is roughly $26 million — the largest dollar event among the six, and the one where the ratio is lowest. The bigger the ratio and the smaller the dollar value, the less the print tells you about the business.

3. Five-day momentum shows who arrived out of nowhere and who was already in motion. Going into Friday: CVRX +3.2%, ONCO -6.3%, MTVA -8.4%, ANIK -11.3%, FLGT -13.9% and BDSX -19.7%. Every one of the five that moved double digits had a negative week behind it, which is what a surprise looks like — the market was not positioned for a Fulgent beat or a Biodesix cut. CVRX is the exception worth flagging: a +3.2% five-day reading into a -40.90% day means the decline was an event gap rather than the end of a slide, and gaps of that size usually need a second session to find a bid.

4. Range position is the most honest number on the board. CVRX at $0.87 is 92% below its 52-week high and printed a new low — a structural repricing, not a pullback. BDSX at $8.53 is 73% below its high but still 62% above its $5.26 low, which is the signature of a stock that ran first and gave it back. ANIK at $14.55 is 36% below its high and 61% above its low: mid-range, where a guidance reset lands rather than a solvency question. FLGT at $23.74 sits 24% below its high, the closest to the top of its range of any name here, and MTVA at $1.43 is 89% below a $13.42 high — a stock whose 52-week range is a reminder of how much dilution and reverse-split history sits behind the current float. ONCO’s pre-split high is not comparable to today’s price at all, which is exactly why split-adjusted interpretation matters more than a range percentage.

5. Cash and dilution is where the two ends diverge cleanly. FLGT holds roughly $652 million in cash and securities, guides to about $630 million at year end, and has $75.6 million of buyback authorisation left. MTVA holds $12.6 million, carries no debt, and is funded by a 26.8% strategic holder into a 2027 readout. ANIK generates a 62% gross margin, guides to a 15–17% adjusted EBITDA margin and is adding about $8 million of contracted payments from a ten-year distribution deal. BDSX ended the quarter with $28.4 million of cash, including $6.3 million of at-the-market proceeds, against a business now guiding to roughly 15% growth instead of the low twenties. CVRX is cutting operating expense to a $99–101 million range at a $56–57 million revenue guide. ONCO has just divided its share count by ten to stay listed. The common thread is not runway: it is whether the next dollar of capital arrives at a price the company sets or a price the market sets.

What This Synthesis Will and Will Not Tell You

This is a one-session sample of 568 companies out of the roughly 600 we attempt; two names were skipped, thirty quotes did not return a usable print, and five prints came back unchanged with no comparable change field and were treated as flat. Nothing here is a recommendation, and one day of price action is weak evidence about any company’s value — particularly on a rebound session where the median rose nearly three percent and a five percent gain was the rule rather than the exception.

What the synthesis will tell you is where the session’s information was concentrated and which class of signal each extreme belongs to. MTVA’s +31.19% is a 68% placebo-adjusted liver-fat reduction and 13.5% weight loss at Day 109, released a session earlier than the market priced it. FLGT’s +27.22% is $90.4 million of quarterly revenue, a 56-cent EPS beat, an improved loss guide and roughly $630 million of projected year-end cash. ONCO’s +26.59% is a 1-for-10 split and a share count falling from 5.89 million to 589,000. BDSX’s -57.01% is a guide cut to $101–103 million and a 12% revenue miss. CVRX’s -40.90% is a 12% prior-authorisation approval rate and a fourth quarter guided below the third. ANIK’s -24.73% is an FDA “not approvable” letter on Hyalofast and flat-to-5% growth in 2027.

What it will not tell you is whether any of those readings survive the fortnight, or how much of Friday’s gain was short covering after a 9.8-to-1 down day rather than a change in expected cash flows — we do not model order flow, borrow availability, changes in short interest or institutional positioning. Three of the six have a dated event inside two weeks: MetaVia’s full Part 3A and 3B data and its 2027 Phase 2 start both sit on the calendar, Biodesix has to show that a 110-rep field force and an October rebound convert into fourth-quarter revenue above the reset bar, and CVRx has to demonstrate that prior-authorisation approvals recover before its cash and opex plan are tested again. For Fulgent, the next test is whether a beat-and-raise holds its gap when the index stops helping; for Anika, whether a 10% grower can hold a mid-range multiple while guiding to flat; and for Onconetix, nothing at all — the split changed the share count, and the next real datapoint is the next filing.

The honest summary is that Friday repriced the cohort’s discount rate and left the tails exactly where they were: decided by documents. A rebound tells you the market changed its mind about the future. It does not tell you anything about any individual company’s facts, and on a day when 416 of 568 names rose, the six that did not move with the tape are the only ones that told us something.

This analysis is compiled from public market data and public company disclosures for informational purposes only. It is not investment advice, an offer, or a solicitation. Positions in individual securities carry risk of loss, including total loss. Readers should conduct their own due diligence.